BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 26613391)

  • 1. Pitting new treatments for chronic lymphocytic leukemia against old ones: how do they fare?
    Shvidel L; Berrebi A
    Expert Rev Hematol; 2016 Mar; 9(3):245-54. PubMed ID: 26613391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Chronic lymphatic leukemia].
    Bergmann M; Wendtner CM
    Dtsch Med Wochenschr; 2015 Apr; 140(7):479-82. PubMed ID: 25826029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic markers and standard management of chronic lymphocytic leukemia.
    Stilgenbauer S
    Hematology Am Soc Hematol Educ Program; 2015; 2015():368-77. PubMed ID: 26637745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment.
    Hallek M
    Am J Hematol; 2015 May; 90(5):446-60. PubMed ID: 25908509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG).
    Cramer P; Langerbeins P; Eichhorst B; Hallek M
    Eur J Haematol; 2016 Jan; 96(1):9-18. PubMed ID: 26332019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment.
    Hallek M
    Am J Hematol; 2013 Sep; 88(9):803-16. PubMed ID: 23720127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
    Robak T; Lech-Maranda E; Robak P
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Chronic lymphocytic leukemia].
    Maurer C; Hallek M
    Dtsch Med Wochenschr; 2013 Oct; 138(42):2153-66. PubMed ID: 24104591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolving Strategies for the Treatment of Chronic Lymphocytic Leukemia in the Upfront Setting.
    Bachow SH; Lamanna N
    Curr Hematol Malig Rep; 2016 Feb; 11(1):61-70. PubMed ID: 26951237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial therapy of chronic lymphocytic leukemia.
    Eichhorst B; Cramer P; Hallek M
    Semin Oncol; 2016 Apr; 43(2):241-50. PubMed ID: 27040702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of real-world treatment patterns in chronic lymphocytic leukemia management before and after availability of ibrutinib in the province of British Columbia, Canada.
    Huang SJ; Gerrie AS; Young S; Tucker T; Bruyere H; Hrynchak M; Galbraith P; Al Tourah AJ; Dueck G; Noble MC; Ramadan KM; Tsang P; Hardy E; Sehn L; Toze CL
    Leuk Res; 2020 Apr; 91():106335. PubMed ID: 32114372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current Treatment of Chronic Lymphocytic Leukemia.
    Jamroziak K; Puła B; Walewski J
    Curr Treat Options Oncol; 2017 Jan; 18(1):5. PubMed ID: 28185174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic lymphocytic leukemia: current and emerging treatment approaches.
    Kay NE; Rai KR; O'Brien S
    Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 22):1-10; quiz 11-2. PubMed ID: 17143256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment.
    Hallek M
    Am J Hematol; 2019 Nov; 94(11):1266-1287. PubMed ID: 31364186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy.
    Ysebaert L; Gross E; Kühlein E; Blanc A; Corre J; Fournié JJ; Laurent G; Quillet-Mary A
    Leukemia; 2010 Jul; 24(7):1310-6. PubMed ID: 20463751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chronic lymphocytic leukemia : treatment concepts in transition].
    Eichhorst B; Hallek M
    Internist (Berl); 2015 Apr; 56(4):374-80. PubMed ID: 25776793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia.
    Ladyzynski P; Molik M; Foltynski P
    Cancer Treat Rev; 2015 Feb; 41(2):77-93. PubMed ID: 25512118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia.
    Short NJ; Keating MJ; Wierda WG; Faderl S; Ferrajoli A; Estrov Z; Smith SC; O'Brien SM
    Cancer; 2015 Nov; 121(21):3869-76. PubMed ID: 26218678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modern concepts in the treatment of chronic lymphocytic leukemia.
    Smolej L
    Hematology; 2009 Oct; 14(5):249-54. PubMed ID: 19843378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. State-of-the-Art Treatment and Novel Agents in Chronic Lymphocytic Leukemia.
    Cramer P; Hallek M; Eichhorst B
    Oncol Res Treat; 2016; 39(1-2):25-32. PubMed ID: 26890007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.